Endocrinol Metab.  2021 Feb;36(1):36-40. 10.3803/EnM.2021.104.

Best Achievements in Translational and Basic Thyroidology in 2020

Affiliations
  • 1Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
  • 2Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, Korea

Abstract

This review discusses articles published in 2020 that presented noteworthy achievements in translational and basic thyroidology. Previously unresolved questions about thyroid hormone receptor actions and signaling mechanisms were answered using various novel in vitro and in vivo models. Using high resolution cryo-electron microscopy, the fine functional structure of thyroglobulin was demonstrated, and new insights into the pathogenesis of thyroid disease were achieved, with a focus on research into thyroid-disrupting chemicals and the gut microbiome. Novel therapeutic approaches were tried in the field of advanced thyroid cancer treatments.

Keyword

Receptors, thyroid hormone; Thyroglobulin; Gastrointestinal microbiome; Thyroid neoplasm; Endocrine disruptors

Reference

1. Krieger TG, Moran CM, Frangini A, Visser WE, Schoenmakers E, Muntoni F, et al. Mutations in thyroid hormone receptor α1 cause premature neurogenesis and progenitor cell depletion in human cortical development. Proc Natl Acad Sci U S A. 2019; 116:22754–63.
Article
2. Moran C, Schoenmakers N, Agostini M, Schoenmakers E, Offiah A, Kydd A, et al. An adult female with resistance to thyroid hormone mediated by defective thyroid hormone receptor α. J Clin Endocrinol Metab. 2013; 98:4254–61.
Article
3. Fauquier T, Romero E, Picou F, Chatonnet F, Nguyen XN, Quignodon L, et al. Severe impairment of cerebellum development in mice expressing a dominant-negative mutation inactivating thyroid hormone receptor alpha1 isoform. Dev Biol. 2011; 356:350–8.
Article
4. Han CR, Wang H, Hoffmann V, Zerfas P, Kruhlak M, Cheng SY. Thyroid hormone receptor α mutations cause heart defects in zebrafish. Thyroid. 2021; 31:315–26.
Article
5. Ferdous A, Wang ZV, Luo Y, Li DL, Luo X, Schiattarella GG, et al. FoxO1-Dio2 signaling axis governs cardiomyocyte thyroid hormone metabolism and hypertrophic growth. Nat Commun. 2020; 11:2551.
Article
6. Franca MM, German A, Fernandes GW, Liao XH, Bianco AC, Refetoff S, et al. Human type 1 iodothyronine deiodinase (DIO1) mutations cause abnormal thyroid hormone metabolism. Thyroid. 2021; 31:202–7.
7. Kus A, Chaker L, Teumer A, Peeters RP, Medici M. The genetic basis of thyroid function: novel findings and new approaches. J Clin Endocrinol Metab. 2020; 105:dgz225.
8. Praestholm SM, Siersbaek MS, Nielsen R, Zhu X, Hollenberg AN, Cheng SY, et al. Multiple mechanisms regulate H3 acetylation of enhancers in response to thyroid hormone. PLoS Genet. 2020; 16:e1008770.
Article
9. Coscia F, Taler-Vercic A, Chang VT, Sinn L, O’Reilly FJ, Izore T, et al. The structure of human thyroglobulin. Nature. 2020; 578:627–30.
Article
10. Knezevic J, Starchl C, Tmava Berisha A, Amrein K. Thyroid-gut-axis: how does the microbiota influence thyroid function? Nutrients. 2020; 12:1769.
Article
11. Fenneman AC, Rampanelli E, Yin YS, Ames J, Blaser MJ, Fliers E, et al. Gut microbiota and metabolites in the pathogenesis of endocrine disease. Biochem Soc Trans. 2020; 48:915–31.
Article
12. Yoo WS, Chung HK. Recent advances in autoimmune thyroid diseases. Endocrinol Metab (Seoul). 2016; 31:379–85.
Article
13. Li Q, Wang B, Mu K, Zhang JA. The pathogenesis of thyroid autoimmune diseases: new T lymphocytes. Cytokines circuits beyond the Th1-Th2 paradigm. J Cell Physiol. 2019; 234:2204–16.
14. Su X, Yin X, Liu Y, Yan X, Zhang S, Wang X, et al. Gut dysbiosis contributes to the imbalance of treg and th17 cells in Graves’ disease patients by propionic acid. J Clin Endocrinol Metab. 2020; 105:dgaa511.
Article
15. Jiang W, Yu X, Kosik RO, Song Y, Qiao T, Tong J, et al. Gut microbiota may play a significant role in the pathogenesis of Graves’ disease. Thyroid. 2021. Jan. 7. [Epub]. https://doi.org/10.1089/thy.2020.0193 .
Article
16. Sun J, Zhao F, Lin B, Feng J, Wu X, Liu Y, et al. Gut microbiota participates in antithyroid drug induced liver injury through the lipopolysaccharide related signaling pathway. Front Pharmacol. 2020; 11:598170.
Article
17. Lee DH. Evidence of the possible harm of endocrine-disrupting chemicals in humans: ongoing debates and key issues. Endocrinol Metab (Seoul). 2018; 33:44–52.
Article
18. Ramhoj L, Hass U, Gilbert ME, Wood C, Svingen T, Usai D, et al. Evaluating thyroid hormone disruption: investigations of long-term neurodevelopmental effects in rats after perinatal exposure to perfluorohexane sulfonate (PFHxS). Sci Rep. 2020; 10:2672.
Article
19. Ramhoj L, Hass U, Boberg J, Scholze M, Christiansen S, Nielsen F, et al. Perfluorohexane sulfonate (PFHxS) and a mixture of endocrine disrupters reduce thyroxine levels and cause antiandrogenic effects in rats. Toxicol Sci. 2018; 163:579–91.
Article
20. Gilbert ME, O’Shaughnessy KL, Axelstad M. Regulation of thyroid-disrupting chemicals to protect the developing brain. Endocrinology. 2020. 161:bqaa106.
Article
21. Kim J, Lee G, Lee YM, Zoh KD, Choi K. Thyroid disrupting effects of perfluoroundecanoic acid and perfluorotridecanoic acid in zebrafish (Danio rerio) and rat pituitary (GH3) cell line. Chemosphere. 2021; 262:128012.
Article
22. Chu S, Kwon BR, Lee YM, Zoh KD, Choi K. Effects of 2-ethylhexyl-4-methoxycinnamate (EHMC) on thyroid hormones and genes associated with thyroid, neurotoxic, and nephrotoxic responses in adult and larval zebrafish (Danio rerio). Chemosphere. 2021; 263:128176.
Article
23. Pozdeyev N, Rose MM, Bowles DW, Schweppe RE. Molecular therapeutics for anaplastic thyroid cancer. Semin Cancer Biol. 2020; 61:23–9.
Article
24. Oh JM, Baek SH, Gangadaran P, Hong CM, Rajendran RL, Lee HW, et al. A novel tyrosine kinase inhibitor can augment radioactive iodine uptake through endogenous sodium/iodide symporter expression in anaplastic thyroid cancer. Thyroid. 2020; 30:501–18.
Article
25. Iniguez-Ariza NM, Bible KC, Clarke BL. Bone metastases in thyroid cancer. J Bone Oncol. 2020; 21:100282.
26. Shin HS, Sun HJ, Whang YM, Park YJ, Park DJ, Cho SW. Metformin reduces thyroid cancer tumor growth in the metastatic niche of bone by inhibiting osteoblastic RANKL productions. Thyroid. 2020. Sep. 15. [Epub]. https://doi.org/10.1089/thy.2019.0851 .
Article
27. Ahn J, Jin M, Song E, Ryu YM, Song DE, Kim SY, et al. Immune profiling of advanced thyroid cancers using fluorescent multiplex immunohistochemistry. Thyroid. 2021; 31:61–7.
Article
28. Pozdeyev N, Erickson TA, Zhang L, Ellison K, Rivard CJ, Sams S, et al. Comprehensive immune profiling of medullary thyroid cancer. Thyroid. 2020; 30:1263–79.
Article
Full Text Links
  • ENM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr